Albemarle Corporation (NYSE:ALB) had its price objective upped by stock analysts at Jefferies Group LLC from $144.00 to $156.00 in a report issued on Thursday. The brokerage currently has a “buy” rating on the specialty chemicals company’s stock. Jefferies Group LLC’s price objective points to a potential upside of 14.64% from the company’s current price.

A number of other research analysts also recently commented on the stock. Royal Bank Of Canada reaffirmed a “buy” rating and issued a $136.00 price target on shares of Albemarle Corporation in a report on Wednesday. Instinet increased their price target on shares of Albemarle Corporation from $134.00 to $146.00 and gave the company a “buy” rating in a report on Monday. KeyCorp reaffirmed a “buy” rating and issued a $125.00 price target on shares of Albemarle Corporation in a report on Sunday, September 3rd. CIBC began coverage on shares of Albemarle Corporation in a report on Thursday, August 17th. They issued an “outperform” rating and a $133.00 price target for the company. Finally, Oppenheimer Holdings, Inc. began coverage on shares of Albemarle Corporation in a report on Wednesday, August 16th. They issued an “outperform” rating and a $133.00 price target for the company. Seven research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. Albemarle Corporation has a consensus rating of “Buy” and a consensus price target of $113.17.

Albemarle Corporation (ALB) traded down 1.18% on Thursday, hitting $134.48. The stock had a trading volume of 653,563 shares. The company’s 50 day moving average price is $117.92 and its 200 day moving average price is $111.37. The firm has a market cap of $14.86 billion, a price-to-earnings ratio of 17.20 and a beta of 1.61. Albemarle Corporation has a 52-week low of $76.32 and a 52-week high of $136.50.

Albemarle Corporation (NYSE:ALB) last announced its quarterly earnings results on Monday, August 7th. The specialty chemicals company reported $1.13 EPS for the quarter, beating the Zacks’ consensus estimate of $1.11 by $0.02. Albemarle Corporation had a net margin of 31.49% and a return on equity of 11.59%. The firm had revenue of $737.25 million during the quarter, compared to the consensus estimate of $735.50 million. During the same quarter last year, the firm earned $0.93 EPS. The firm’s revenue for the quarter was up 10.1% compared to the same quarter last year. Analysts expect that Albemarle Corporation will post $4.37 EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Jefferies Group LLC Raises Albemarle Corporation (ALB) Price Target to $156.00” was originally reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this piece of content on another website, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this piece of content can be viewed at https://theolympiareport.com/2017/09/21/jefferies-group-llc-raises-albemarle-corporation-alb-price-target-to-156-00.html.

In other news, EVP Matthew Juneau sold 5,397 shares of the firm’s stock in a transaction that occurred on Thursday, August 24th. The shares were sold at an average price of $115.77, for a total transaction of $624,810.69. Following the transaction, the executive vice president now directly owns 360 shares of the company’s stock, valued at $41,677.20. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Chairman Luther C. Iv Kissam sold 50,000 shares of the firm’s stock in a transaction that occurred on Friday, July 7th. The stock was sold at an average price of $110.08, for a total transaction of $5,504,000.00. Following the transaction, the chairman now directly owns 252,917 shares in the company, valued at $27,841,103.36. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 91,897 shares of company stock worth $10,215,486. Corporate insiders own 0.74% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Northwestern Mutual Wealth Management Co. boosted its stake in shares of Albemarle Corporation by 2.1% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 968 shares of the specialty chemicals company’s stock valued at $102,000 after purchasing an additional 20 shares in the last quarter. Carroll Financial Associates Inc. boosted its stake in shares of Albemarle Corporation by 0.3% during the second quarter. Carroll Financial Associates Inc. now owns 982 shares of the specialty chemicals company’s stock valued at $103,000 after purchasing an additional 3 shares in the last quarter. Highlander Capital Management LLC bought a new position in shares of Albemarle Corporation during the second quarter valued at approximately $106,000. Smithfield Trust Co. boosted its stake in shares of Albemarle Corporation by 16.1% during the second quarter. Smithfield Trust Co. now owns 1,008 shares of the specialty chemicals company’s stock valued at $106,000 after purchasing an additional 140 shares in the last quarter. Finally, Advisory Services Network LLC boosted its stake in shares of Albemarle Corporation by 43.7% during the second quarter. Advisory Services Network LLC now owns 1,273 shares of the specialty chemicals company’s stock valued at $134,000 after purchasing an additional 387 shares in the last quarter. Hedge funds and other institutional investors own 83.73% of the company’s stock.

Albemarle Corporation Company Profile

Albemarle Corporation is a global developer, manufacturer and marketer of highly-engineered specialty chemicals. The Company operates through three segments: Lithium and Advanced Materials, Bromine Specialties and Refining Solutions. Lithium and Advanced Materials segment consist of two product categories: Lithium and Performance Catalyst Solutions.

Analyst Recommendations for Albemarle Corporation (NYSE:ALB)

Receive News & Ratings for Albemarle Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albemarle Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.